Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer

BACKGROUND: Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers. This study reviewed the HPD in patients with AGC treated with nivolumab or irinotec...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoki, Masahiko, Shoji, Hirokazu, Nagashima, Kengo, Imazeki, Hiroshi, Miyamoto, Takahiro, Hirano, Hidekazu, Honma, Yoshitaka, Iwasa, Satoru, Okita, Natsuko, Takashima, Atsuo, Kato, Ken, Higuchi, Kazuhide, Boku, Narikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555603/
https://www.ncbi.nlm.nih.gov/pubmed/31231567
http://dx.doi.org/10.1136/esmoopen-2019-000488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555603/
https://www.ncbi.nlm.nih.gov/pubmed/31231567
http://dx.doi.org/10.1136/esmoopen-2019-000488

Ejemplares similares